Health Care Equities under Review -- Research on PerkinElmer, Quintiles Transnational Holdings, WuXi PharmaTech Cayman, and ICON
PR Newswire - Tue Apr 15, 11:54AM CDT
The trading session on Monday, April 14, 2014 ended on a higher note as the S&P 500 finished the session 0.82% higher at 1,830.61 and the NASDAQ Composite closed at 4,022.69, up 0.57%. The Dow Jones Industrial Average finished at 16,173.24, up 0.91%. During the session, all the ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 648.05, up 0.51%, whereas the same has declined 1.86% in the last three months. Investor-Edge has initiated coverage on the following equities: PerkinElmer Inc. (NYSE: PKI), Quintiles Transnational Holdings Inc. (NYSE: Q), WuXi PharmaTech Cayman Inc. (NYSE: WX) and ICON PLC (NASDAQ: ICLR). Free technical research on PKI, Q, WX and ICLR can be downloaded upon signing up at:
Quest Diagnostics Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 4:32PM CDT
Adjusted earnings per share of Quest Diagnostic came in at $1.03, beating the Zacks Consensus Estimate of 94 cents by 9.6%, and exceeding the company's prior-year earnings by 2%.
Weakness Seen in WellCare Health Plans (WCG): Stock Falls 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 7:33AM CDT
WellCare Health Plans (WCG) fell nearly 6% in the last trading session amid huge volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
Product Launches, Acquisitions, Closed Offerings, Divestitures, and Financial Results - Analyst Notes on Dr. Reddy's, ICON, Endocyte, BioScrip, and DepoMed
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Dr. Reddy's Laboratories Ltd. (NYSE: RDY), ICON plc (NASDAQ: ICLR), Endocyte, Inc. (NASDAQ: ECYT), BioScrip Inc. (NASDAQ: BIOS), and DepoMed Inc. (NASDAQ: DEPO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Will Clinical Trial Specialist Icon's Latest Base Get Good Results?
at Investor's Business Daily - Fri Apr 04, 12:30PM CDT
Today we'll look at Icon (ICLR), an Irish provider of outsourced development services for the pharmaceutical, biotech and medical device industries. They specialize in clinical research services. Last month, Icon announced they would acquire Aptiv...
Magellan Announces CDMI Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 6:20PM CDT
In order to consolidate its foothold in Newport, Magellan inked a deal to acquire privately held CDMI, LLC
ICON Up 20.1% Since SmarTrend Uptrend Call (ICLR)
Comtex SmarTrend(R) - Tue Apr 01, 9:21AM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on December 26th, 2013 at $39.72. In approximately 3 months, ICON has returned 20.06% as of today's recent price of $47.68.
Aptiv Solutions to be Acquired by ICON
Business Wire - Mon Mar 31, 8:03AM CDT
Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency, and productivity of product development today announced that it has agreed, subject to certain closing conditions, to be acquired by ICON plc, (NASDAQ:ICLR), for a cash consideration of $143.5 million. Aptiv Solutions is owned by The Halifax Group, SV Life Sciences, Comvest Partners and Management.
ICON to buy USD143.5m Aptiv Solutions to enhance capabilities in adaptive and medical device trials
M2 - Mon Mar 31, 5:37AM CDT
Outsourced pharmaceutical development services ICON (NasdaqGS:ICLR) said on Monday that it has entered into an agreement to acquire Aptiv Solutions for USD143.5m in cash.
ICON to Acquire Aptiv Solutions
Business Wire - Mon Mar 31, 5:00AM CDT
ICON plc, (NASDAQ:ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain closing conditions, to acquire Aptiv Solutions for a cash consideration of $143.5 million. Aptiv Solutions is owned by The Halifax Group, SV Life Sciences, Comvest Partners and Management.
4 Disruptive Stocks Biotechs Depend On
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 5:30PM CDT
It's easy for investors to fall into the trap of chasing markets higher and lower, especially when the media machine hypes booms and busts. However, investors that chase market pops and drops rarely come out ahead in the long haul. Instead,...
Omnicare Unit Gets Accreditation but Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 12:00PM CDT
Shares of OCR have been on a downtrend since the announcement of its lower-than-expected earnings on Feb 19, 2014.
ICON Has Returned 17.6% Since SmarTrend Recommendation (ICLR)
Comtex SmarTrend(R) - Mon Mar 24, 5:18PM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on December 26th, 2013 at $39.72. In approximately 3 months, ICON has returned 17.59% as of today's recent price of $46.70.
Falling Earnings Estimates Signal Weakness Ahead for Catamaran (CTRX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 7:46AM CDT
Catamaran has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
PAREXEL Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 2:20PM CDT
PAREXEL has delivered positive earnings surprises in 3 of the last 4 quarters with an average beat of 14.83%.
ICON Shares Up 22.0% Since SmarTrend's Buy Recommendation (ICLR)
Comtex SmarTrend(R) - Mon Mar 17, 11:12AM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on December 26th, 2013 at $39.72. In approximately 3 months, ICON has returned 22.01% as of today's recent price of $48.46.
Charles River Acquires CRO Division of Galapagos - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 4:40PM CDT
In a move to advance its position in the fast-growing outsourced discovery services market, Charles River Laboratories entered into a definitive agreement to acquire the CRO services division of Galapagos NV.
Intrexon (XON) Catches Eye: Stock Adds 11.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:25AM CDT
Intrexon was a big mover last session, with shares rising over 11% on the day.
Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 13, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rs95v7/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting. The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service. The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations. The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW). The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions. The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Introduction Executive Summary Global Pharmacovigilance Market Dynamics Global Pharmacovigilance Market, by Clinical Trial Phases Global Pharmacovigilance Market, By Type of Methods Global Pharmacovigilance Market, by Type of Service Providers Global Pharmacovigilance Market, by Geography Global Pharmacovigilance Market Share Analysis Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/rs...ovigilance About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.